Ajanta Pharma Limited · NSE:AJANTPHARM
Ajanta Pharma — Q3 FY2013 Earnings Presentation
18 slides from Ajanta Pharma's earnings presentation, December 2012
Slide 1: Ajanta Pharma - Investors Update
Ajanta Pharma - Investors Update
Slide 2: Ajanta – The Global Player
Ajanta – The Global Player Ajanta has presence in following markets India Emerging Markets Specialty segments Africa, Asia & Latin America Regulated Markets USA
Slide 3: India Business
India Business Strong presence in Ophthal, Derma, Cardio Overall ranked 45th as per IMS (MAT Dec’12) Ophthal 6th, Derma 14th & Cardio 29th (MAT Nov’12) Leadership in many sub-therapeutic segments Many 1st in Indian market ahead of competition
Slide 4: India Business
India Business Focus on innovation for patient convenience Forming about 35% of company’s sales 2000+ strong field force Rich new product pipeline for future growth
Slide 5: India Business
India Business Ajanta’s Speciality CAGR (5 years) Segment CAGR % (FY 12) Ophthalmology 20% Ajanta’s Domestic FY’12 Dermatology 29% Others, 7% Cardio Cardiology 21% Institution 21% 23% Derma 27% Ophthal 22%
Slide 6: Emerging Market Business
Emerging Market Business Innovative Brand Enjoying Brand Presence in Africa, Asia portfolio as per Leadership in many and Latam individual country’s need markets Expertise in product 1400+ Brand 300 strong field force in registrations by providing registrations across 25+ countries high quality doss
Slide 7: Regulated Market Business
Regulated Market Business Total ANDA – 11, Received approval for Approved – 2, Sildenafil Tablets from Under Approval - 9 UK in Q3 Launched 1st product Other EU countries i.e., Risperidone (Anti approval for same Depression) in Q2, FY’13 product is awaited Expected to launch in Target to file 5-6 AN
Slide 8: Ajanta's Infrastructure
Ajanta’s Infrastructure Formulation Manufacturing 3 Facilities in Aurangabad (1 USFDA, UKMHRA, WHO Pre-Q, approved) 1 Facility at Mauritius 2 more coming up in Gujarat (Investment Rs.400Crs) API Manufacturing 1 Facility in Aurangabad (Captive pilot plant ) Research & Development – Kandivli,
Slide 9: Consolidated Revenue from operation
Consolidated Revenue from operation 684 (` Crs.) 508 410 352 311 259 231 200 146 123 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Slide 10: Consolidated Profit after tax
Consolidated Profit after tax 77 (` Crs.) 51 34 25 22 15 12 10 1 2 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Slide 11: Consolidated P & L
Consolidated P & L ` Crores Mar-08 Mar-09 Mar-10 Mar-11 Mar-12 TOTAL INCOME 311 352 410 508 684 Materials 140 127 140 173 230 Personnel 31 43 48 64 94 R&D Exp. 10 16 20 25 37 Other Exp 77 99 123 148 175 Sub Total 258 284 331 409 537 EBITDA 53 68 80 99 147 EBIT 45 53 59 74 115 Interest 16 24 20 18 24
Slide 12: Consolidated Balance Sheet
Consolidated Balance Sheet ` Crores Mar-08 Mar-09 Mar-10 Mar-11 Mar-12 Equity share capital 12 12 12 12 12 Reserves & surplus 123 145 173 217 286 Loans 174 250 228 191 200 Total 309 407 413 419 498 Fixed assets 126 193 215 231 249 Investments 8 8 8 8 8 Net current assets 175 205 189 180 241 Total 30
Slide 13: Consolidated Per Share Statistics
Consolidated Per Share Statistics ` Mar-08 Mar-09 Mar-10 Mar-11 Mar-12 EPS 9 11 14 21 33 Cash EPS 13 17 23 32 46 EBITDA per share 22 29 34 42 62 Book value per share 57 67 78 97 126 Dividend/share Rs. 2.5 2.5 3.5 5.0 7.5 Numbers are @5/- face value
Slide 14: Consolidated Profitability Ratios
Consolidated Profitability Ratios Particulars Mar-08 Mar-09 Mar-10 Mar-11 Mar-12 EBITDA margin 17% 19% 19% 20% 22% PAT margin 7% 7% 8% 10% 11% RONW 16% 16% 18% 22% 26% ROCE 17% 17% 19% 24% 30%
Slide 15: Q3 – Standalone Performance
Q3 – Standalone Performance `Crs. 40% 76% Revenue EBITDA 229 (164) 60 (34) PBT PAT 49 (22) 33 (19) 117% 76% Figures indicated in brackets are previous year’s figures
Slide 16: 9M Stand Alone Performance
9M Stand Alone Performance Revenue PBT 73% 73% Rs.590crs Rs.103crs Rs.74crs Rs.139crs (Rs.428crs) (Rs.49crs) (Rs.43crs) (Rs.80crs) 38% 113% EBITDA PAT Figures indicated in brackets are previous year’s figures
Slide 17: Strategic Vision
Strategic Vision Increase market share in existing markets through penetration Continue to focus on specialty segments through innovation Enhance productivity for domestic field force New product launches in global markets More product launches in USA with niche & IR product basket Entry in Europe f
Slide 18: Thank You
Thank You SAFE HARBOUR STATEMENT This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. The Company also d